Bezlotoxumab: A Key Deterrent for Recurrent Hypervirulent Clostridioides difficile (ACG 2026) - Aug 29, 2026 - Abstract #P3658; Pres time: Oct 12, 2026; 10:30 AM - 04:15 PM; Location: Exhibit Halls A - D (Level 3); "We present a case of recurrent CD requiring bezlotoxumab in addition to oral fidaxomicin and intravenous metronidazole after failure of oral vancomycin and oral fidaxomicin. This case highlights the need to restructure the CD diagnostic algorithm to include earlier hypervirulent strain testing. Figure: Figure 1: Computed tomography of abdomen and pelvis demonstrating inflammatory changes of the sigmoid colon with peri-appendiceal fat stranding"
Endocrine Disorders • Hypotension • Infectious Disease • Metabolic Disorders
|
|
Yash Vinod. Bhagat; MD; Gennadiy Grutman; MD
|